Full-Time

Vice President

Quality

Remix Therapeutics

Remix Therapeutics

11-50 employees

Biotech firm developing mRNA-degrading therapies

Compensation Overview

$293k - $358k/yr

+ Bonus + Equity

Belmont, MA, USA

In Person

Master's, MBA, PhD

Category
Biology & Biotech (1)
Required Skills
Risk Management
Google Cloud Platform

Get referred to Remix Therapeutics

See people who can refer or advise you

Requirements
  • Masters degree or higher in Biology, Chemistry, Pharmaceutical Sciences, Engineering, or a related scientific discipline
  • 15+ years of progressive pharmaceutical/biotech industry experience, with 10+ years in quality management and leadership roles of increasing scope
  • Proven track record building, leading, and scaling quality organizations at clinical-stage and/or commercial-stage companies
  • Deep expertise in GCP and GMP compliance
  • Demonstrated success leading or hosting FDA and/or EMA GxP inspections; direct experience managing inspection responses and regulatory action items
  • Expert knowledge of FDA, EMA, and ICH guidelines and regulations applicable across the drug development lifecycle
  • Experience providing quality oversight of small molecule CMOs and clinical CROs in a virtual or hybrid operating model
  • Exceptional leadership presence, integrity, and judgment; thrives in a dynamic, fast-paced environment where agility and accountability coexist
  • Familiarity with oncology drug development and oncology-specific clinical quality considerations
  • Working knowledge of EU GMP requirements and experience with dual US/EU regulatory programs
Responsibilities
  • Define and drive the Quality vision, objectives, and culture of Remix, establishing quality as a strategic enabler of the company's mission
  • Design, develop, and oversee a risk-based, phase-appropriate Quality Management System spanning pre-clinical through commercialization
  • Ensure the QMS meets FDA, EMA, and ICH standards while remaining agile and fit-for-purpose for a clinical-stage organization
  • Build and lead Remix's quality organization from the ground up; hire and develop a small, high-impact team while establishing the infrastructure, processes, and culture to scale alongside the pipeline
  • Lead Health Authority inspections and all inspection readiness activities across GxP disciplines
  • Serve as primary quality point of contact in regulatory interactions and submissions; ensure quality sections of INDs, NDAs/BLAs, MAAs, and other submissions meet agency expectations
  • Maintain comprehensive inspection readiness program ensuring audit readiness
  • Monitor evolving regulatory requirements, ICH guidance, and industry best practices; assess impact and implement updates to QMS
  • Provide GCP quality oversight across all clinical development programs, including protocol development, site qualification, monitoring, and data integrity
  • Partner with Drug Safety/Pharmacovigilance to provide quality oversight of PV activities, including SAE reconciliation, SUSAR reporting, PBRER/DSUR quality review, and inspection readiness for safety databases and processes
  • Ensure pharmacovigilance quality agreements and audit programs are in place with CROs and technology vendors
  • Collaborate with Clinical Operations, Biostatistics, and Regulatory Affairs to embed quality standards in trial execution
  • Oversee quality aspects of small molecule drug substance and drug product manufacturing, including batch review and product release at CMOs
  • Establish and maintain supplier qualification, oversight, and performance management programs for CMOs and CROs
  • Lead GMP vendor qualification audits and for-cause audits; maintain risk-stratified audit schedule
  • Partner with CMC, Regulatory, and Supply Chain to ensure product quality across supply chain from development through commercial launch
  • Own and continuously improve core QMS elements: document management, change control, deviation and CAPA management, risk management, and quality metrics
  • Design and implement a robust GxP training program; ensure training compliance is maintained across all relevant functions and third-party partners
  • Leverage quality metrics and KPIs to provide executive leadership with meaningful data-driven insights on quality performance and risk

Remix Therapeutics develops medicines for rare diseases with a focus on targeted mRNA degradation. Its lead product REM 422 is an oral small molecule that degrades messenger RNA to stop production of disease-causing proteins. REM 422 is in Phase 1 trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, with FDA Orphan Drug Designation to support development. Remix funds its R&D through grants and partnerships, aiming to bring safe, effective therapies to patients and expand its portfolio.

Company Size

11-50

Company Stage

Growth Equity (Venture Capital)

Total Funding

$224.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Get referred to Remix Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 24, 2026 financing raised $100 million, funding operations into 2028.
  • SEC filing on August 6, 2026 confirms closing path and 2028 runway.
  • 2027 registrational ACC data and AML/HR-MDS readouts create multiple catalysts.

What critics are saying

  • December 24, 2026 is the outside date; failure kills the Passage merger.
  • REM-422 dominates value; any weak 2027 ACC or AML data crushes valuation.
  • Passage holders receive only 7% ownership, signaling leverage and integration fragility.

What makes Remix Therapeutics unique

  • REM-422 targets MYB, a historically undruggable cancer driver, with oral dosing.
  • June 24, 2026 merger preserves Remix’s RNA-processing platform and Nasdaq access.
  • Remaster platform reprograms RNA processing, creating multiple shots on goal beyond REM-422.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

4%
Pharma Journalist
Jun 25th, 2026
Remix Therapeutics to merge with Passage Bio.

Remix Therapeutics to merge with Passage Bio. On Jun 25, 2026 Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and other serious diseases. The deal is backed by a new $100 million private financing, providing the merged company with the resources needed to advance its clinical pipeline through several key development milestones. Following the completion of the transaction, the combined company will operate under the name Remix Therapeutics, Inc. and is expected to trade on the Nasdaq stock exchange under the ticker symbol "RMTX." Alongside the merger announcement, Remix revealed that it has secured commitments for an oversubscribed private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management, Forge Life Science Partners, existing investors, and several other institutional investment firms. The financing is expected to close immediately before the merger is finalized. The combined company expects its cash position, including proceeds from the private placement, to fund operations into 2028. The funding is intended to support several important clinical milestones, including data from the registrational Phase 2 trial of REM-422 in Adenoid Cystic Carcinoma (ACC), results from a Phase 1 trial evaluating the therapy in Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as continued investment in Remix's discovery pipeline. The merger strengthens Remix's position as it develops a new class of small-molecule medicines designed to modulate RNA processing. Unlike conventional therapies that target proteins directly, Remix's platform focuses on controlling how RNA is processed inside cells, offering the potential to treat diseases driven by genetic abnormalities that have historically been difficult to target with existing drugs. At the center of the company's pipeline is REM-422, an orally administered mRNA degrader that targets MYB, a transcription factor involved in several cancers. MYB has long been considered one of the most challenging cancer targets for drug developers, making REM-422 a potentially significant advance if ongoing clinical studies continue to produce positive results. Peter Smith, Ph.D., co-founder and Chief Executive Officer of Remix Therapeutics, described the merger as a transformative milestone for the company. He said the transaction provides the financial strength and operational support needed to accelerate the development of RNA-targeted medicines while expanding the company's proprietary platform. Smith added that the financing and merger position Remix to rapidly advance REM-422 and other pipeline candidates, with the goal of delivering innovative treatment options for patients with cancers that currently have limited therapeutic choices. For Passage Bio, the agreement follows an extensive review of strategic alternatives aimed at maximizing shareholder value. President and Chief Executive Officer Dr. Will Chou said Remix emerged as the ideal partner because of its differentiated RNA processing technology and encouraging early clinical data for REM-422 in adenoid cystic carcinoma. Chou noted that the ongoing registrational study, combined with the company's experienced leadership team, offers Passage Bio shareholders the opportunity to participate in a clinical-stage biotechnology company with a clearly defined path toward pivotal clinical data. The merger reflects growing investor confidence in RNA-based drug development, an area that has attracted increasing attention across the biotechnology industry. By combining Passage Bio's public company infrastructure with Remix's clinical-stage pipeline and fresh capital, the new organization aims to accelerate the development of innovative RNA-targeted therapies and expand treatment options for patients with difficult-to-treat cancers.

BioSpace
Jun 25th, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Boston Cambridge Biotech Networks
Jun 25th, 2026
Remix Therapeutics secures $100M and a reverse merger.

Remix Therapeutics secures $100M and a reverse merger. June 25, 2026 BCBN news, syndication comments off on remix therapeutics secures $100M and a reverse merger. The deal with Passage Bio includes commitments for $100 million in private placement financing led by Decheng Capital. Click here to view original post

MarketScreener
Jun 24th, 2026
Passage Bio and Remix Therapeutics merge in $100M deal to advance RNA cancer therapies

Passage Bio and Remix Therapeutics have announced a definitive merger agreement, with the combined company to operate as Remix Therapeutics and trade on Nasdaq under ticker symbol "RMTX". Upon closing, pre-merger Passage Bio shareholders will own approximately 7% of the combined entity, whilst Remix stockholders will hold 93%. Concurrent with the merger, Remix has secured an oversubscribed $100 million private placement financing led by Decheng Capital. The funding is expected to support operations into 2028 and deliver several clinical readouts for Remix's lead programme, REM-422, an orally available mRNA degrader targeting MYB, in 2027. The transaction, unanimously approved by both boards, is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary closing conditions. The combined company will be led by Remix CEO Peter Smith.

The Manila Times
Nov 3rd, 2025
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference

Remix Therapeutics to present at Guggenheim Second Annual Healthcare Innovation Conference. WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025 at 2:15 PM ET The Remix management team will also be hosting one-on-one meetings with investors. For those investors interested in scheduling a meeting, please contact your Guggenheim representative. About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com.